The median progression-free survival of patients with treatment-naive EGFR-mutated NSCLC and patients who acquired resistance to first- or second-generation EGFR-TKIs who received osimertinib was 19 or 10 months, respectively [9,10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.